Alteration of pallidal cholinergic activity in MPTP-treated monkeys: effect of dihydro-alpha-ergocryptine (DEK).
Monkeys, intravenously administered with MPTP at the dose of 0.3 mg/kg for 5 consecutive days, develop a severe Parkinson-like syndrome. Cholinergic enzyme activities are increased in the internal segment of the globus pallidus (GPi) and into a lesser extent in the external globus pallidus (GPe). Cholinergic activities are not significantly affected in the caudate and putamen nor in the frontal, parietotemporal, occipital cortices and in the cerebellum. The treatment of the animals twice daily for 2 weeks with dihydro-alpha-ergocryptine (DEK) starting 5 days before the first MPTP administration counteracts the neurotoxin-induced alteration in the internal pallidum and ameliorates some motor related parkinsonian symptoms.
Curti
D
D
Institute of Pharmacology, Faculty of Sciences, University of Pavia, Italy.
Izzo
E
E
Benzi
G
G
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000037:antagonists & inhibitors; D000110:Acetylcholinesterase / Q000378:metabolism*; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000201:enzymology / Q000503:physiopathology*; D002795:Choline O-Acetyltransferase / Q000378:metabolism*; D004088:Dihydroergotoxine / Q000494:pharmacology*; D005917:Globus Pallidus / Q000187:drug effects / Q000201:enzymology / Q000503:physiopathology*; D020267:MPTP Poisoning; D008252:Macaca fascicularis; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D009928:Organ Specificity; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000201:enzymology / Q000503:physiopathology*; D011187:Posture; D011768:Pyruvate Dehydrogenase Complex / Q000378:metabolism*; D013997:Time Factors; D014202:Tremor
D011768:Pyruvate Dehydrogenase Complex; D004088:Dihydroergotoxine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D002795:Choline O-Acetyltransferase; D000110:Acetylcholinesterase